Novaliq GmbH
https://www.novaliq.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novaliq GmbH
OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.
Bausch + Lomb Dry Eye Franchise Ahead Of Growth Targets
Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.
Sylentis Piles On Another Failure In Dry Eye
The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.
What’s In Store For Sun’s Key Specialty Drugs Including Melanoma Asset
An "uncontested market" in the neoadjuvant setting potentially awaits Sun’s partnered melanoma asset Nidlegy, while competition heats up for products like Cequa in the US. Scrip pieces together management commentary and analysts’ outlook on some of the key specialty therapies that India’s top-ranked drug maker is building out.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Other Names / Subsidiaries
-
- Novaliq Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice